1196153-28-2

Basic information

• Product Name: 6-BroMo-2,2-diMethyl-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-one
• Synonyms: 6-BroMo-2,2-diMethyl-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-one
• CAS NO: 1196153-28-2
• Molecular Formula: C₉H₉BrN₂O₂
• Molecular Weight: 257.08396
• Mol File: 1196153-28-2.mol

Chemical Properties

• Boiling Point: 394.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.533±0.06 g/cm3(Predicted)
• PKA: 10.25±0.40(Predicted)
• CAS DataBase Reference: 6-BroMo-2,2-diMethyl-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-2,2-diMethyl-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-one(1196153-28-2)
• EPA Substance Registry System: 6-BroMo-2,2-diMethyl-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-one(1196153-28-2)

Safety Data

• Hazardous Substances Data: 1196153-28-2(Hazardous Substances Data)

Upstream product

• 600-00-0 ethyl 2-bromoisobutyrate 
• 934758-27-7 2-amino-6-bromo-3-hydroxypyridine 
• 1373771-94-8 C₁₀H₁₁BrN₂O₅ 
• 1373771-93-7 methyl 2-methyl-2-[(2-nitropyridin-3-yl)oxy]propanoate 
• 1303588-10-4 ethyl 2-((6-bromo-2-nitropyridin-3-yl)oxy)-2-methylpropanoate 
• 443956-08-9 6-bromo-2-nitropyridin-3-ol 
• 15128-82-2 3-hydroxy-2-nitropyridine 

Downstream Products

• 1303588-12-6 2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 
• 1303583-09-6 2,2-dimethyl-N-(pyridin-4-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide 
• 1303585-09-2 (S)-6-(3-(3-fluoropyrrolidin-1-yl)phenyl)-2,2-dimethyl-N-(5-methylpyridin-3-yl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide 
• 1303588-16-0 methyl 3-(2,2-dimethyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)benzoate 
• 1303588-17-1 3-(2,2-dimethyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)benzoic acid 
• 1303588-18-2 (3-(2,2-dimethyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)phenyl)(pyrrolidin-1-yl)methanone 
• 1303588-19-3 2,2-dimethyl-6-(3-(pyrrolidin-1-ylmethyl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 
• 1303584-47-5 2,2-dimethyl-N-(5-methylpyridin-3-yl)-6-(3-(pyrrolidin-1-ylmethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide 
• 1303588-20-6 3-(2,2-dimethyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-N,N-dimethylbenzamide 
• 1303588-21-7 1-(3-(2,2-dimethyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)phenyl)-N,N-dimethylmethanamine 
• 1303585-44-5 6-(3-((dimethylamino)methyl)phenyl)-2,2-dimethyl-N-(pyridin-3-yl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide 
• 1373771-91-5 methyl-2-methyl-2-[(2-nitropyridin-3-yl)oxy]propanoate 

Relevant articles and documents

COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS

Provided are compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.

Macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one and pharmaceutical composition and application thereof

The present invention relates to a macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one as shown in the formula (I) and/or a pharmaceutically acceptable salt thereof, and a composition of a compound of the formula (I) and/or a pharmaceutically acceptable salt thereof, a preparation method thereof, application thereof as a Wee1 inhibitor and application thereof as a sensitizer for cancer chemotherapy or radiotherapy. The macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one can effectively inhibit Wee1 and related signaling pathways, and has good cancer treatment and/or relieving effect.The formula is shown in the description.

SYK INHIBITORS

The present disclosure a Syk compound inhibitors, including state cancer and inflammation and various disease States thereof in the treatment of relates to the use of. In one aspect a particular embodiment, . given by formula I which is marked as a chemical structure of compound. In formula said, X 1, X 2, X 3, R 2, R 3, R 4, R 5, and Y has described herein is. The present disclosure of a formula I compounds or a pharmaceutically acceptable salt of pharmaceutical compositions including, mediated by Syk and to treat conditions a employing these compounds and compositions further provides a method. (by machine translation)

Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6)

Abstract Oxabicyclooctane linked 1,5-naphthyridinyl-pyridoxazinones are novel broad-spectrum bacterial topoisomerase inhibitors (NBTIs) targeting bacterial DNA gyrase and topoisomerase IV at a site different than quinolones. Due to lack of cross-resistance to known antibiotics they present excellent opportunity to combat drug-resistant bacteria. A structure activity relationship of the pyridoxazinone moiety is described in this Letter. Chemical synthesis and activities of NBTIs with substitutions at C-3, C-4 and C-7 of the pyridoxazinone moiety with halogens, alkyl groups and methoxy group has been described. In addition, substitutions of the linker NH proton and its transformation into amide analogs of AM-8085 and AM-8191 have been reported. Fluoro, chloro, and methyl groups at C-3 of the pyridoxazinone moiety retained the potency and spectrum. In addition, a C-3 fluoro analog showed 4-fold better oral efficacy (ED50 3.9 mg/kg) as compared to the parent AM-8085 in a murine bacteremia model of infection of Staphylococcus aureus. Even modest polarity (e.g., methoxy) is not tolerated at C-3 of the pyridoxazinone unit. The basicity and NH group of the linker is important for the activity when CH2 is at the linker position-8. However, amides (with linker position-8 ketone) with a position-7 NH or N-methyl group retained potency and spectrum suggesting that neither basicity nor hydrogen-donor properties of the linker amide NH is essential for the activity. This would suggest likely an altered binding mode of the linker position-7,8 amide containing compounds. The amides showed highly improved hERG (functional IC50 >30 μM) profile.

Rational design and synthesis of novel Syk-kinase inhibitors

Molecular modeling and subsequent synthesis of novel Syk-kinase inhibitors, 7H-pyrrolo[2,3-d]pyrimidine and 1,3,5-triazine derivatives, have been carried out. The best of the obtained compounds demonstrated to inhibit Syk-kinase activity at IC50/sub

BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.